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Abstract. The leukocyte integrins (CDll/CD18 or
ß2-type integrins) are expressed exclusively on leuko-
cytes and participate in many adhesion-dependent func-
tions (Arnaout, M .A . 1990. Blood. 75 :1037-1050 ;
Springer, T. A . 1990 . Nature. (Load .) 346:425-434 ;
Dustin, M . L ., and T. S . Springer. 1991 . Annu. Rev .
Immunol. 9:27-66) . The avidity of leukocyte integrin
binding to their ligands or counter-receptors is depen-
dent upon response to intracellular signals (Wright,
S. D., and B. C . Meyer. 1986. J . Immunol. 136 :1759-
1764 ; Dustin, M . A ., and T. S . Springer. 1989. Na-
ture (Lond.) . 341 :619-624) . We have investigated the
effects of a novel mAb (mAb 24) which defines a leu-
kocyte integrin a subunit epitope that is Mgt+-depen-
dent and may be used as a "reporter" of the activation
state of these receptors (Dransfield, I., and N . Hogg .
1989. EMBO (Eur. Mol. Biol. Organ) J. 8 :3759-3765 ;
Dransfield, L, A.-M . Buckle, and N . Hogg . 1990. Im-
munol. Rev . 114:29-44 ; Dransfield, L, C . Cabanas,
A . Craig, and N . Hogg . 1992 . J . Cell Biol.) Data is
T
HE three leukocyte integrins, lymphocyte function-
associated antigen-1 (LFA-1), complement receptor
type 3 (CR3)/Mac-1, and p150,95 are heterodimeric
molecules each comprising a uniquea subunit noncovalently
associated with a common 02 subunit (Sanchez-Madrid et
al ., 1983) . The roles of these molecules inimmune functions
are best characterized for LFA-1(CDlla/CD18) and CR3-
(CDl lb/CDl8) . Antibody blocking studies have demonstrated
a key role for LFA-1 in many cellular interactions of leuko-
cytes . CR3 is important in functions such as myeloid cell
phagocytosis, adherence to activated endothelium and che-
motaxis (Arnaout, 1990 ; Springer, 1990 ; Smith et al ., 1989) .
These activities are thought to represent in vitro correlates
of the response to tissue inflammation .
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presented to show that this mAb inhibits monocyte-
dependent, antigen-specific T cell proliferation and
IL-2-activated natural killer cell assays which are both
dependent on lymphocyte function-associated antigen-1
(LFA1), and complement receptor type 3 (CR3)-medi-
ated neutrophil chemotaxis to f-Met-Leu-Phe . This
inhibitory effect is not caused by the prevention of
receptor/ligand binding because LFA-1/ICAM-1, LFA-1/
ICAM-2,3 and CR3/iC3b interactions are, under acti-
vating conditions, promoted rather than blocked by
mAb 24 . As it does not interfere with mitogen-stimu-
lated T cell proliferation, it is unlikely that mAb 24
transduces a "negative" or antiproliferative signal to
the T cells to which it is bound . Using a model system
of transient activation of LFA-1, we have found that
mAb 24 prevents "deadhesion" of receptor/ligand pairs,
possibly locking leukocyte integrins in an "active" con-
formation . It is speculated that inhibition of leukocyte
integrin function by this mAb reflects the necessity for
dynamic leukocyte integrin/ligand interactions .
The avidity ofCR3 for ligand can be regulated by cellular
activation as shown by studies using phorbol esters and other
stimulants such as f-Met-Leu-Phe (Wright and Meyer, 1986 ;
Buyon et al ., 1988 ; Lo et al., 1989) . In addition, the interac-
tion of LFA-1 with its ligand, termed intercellular adhesion
molecule-1 (ICAM-1, CD54) (Rothlein et al ., 1986), is tran-
siently induced in response to T cell receptor cross-linking
using CD3 mAbs, thus, providing a mechanism for strength-
ening initial antigen-specific T cell-target interactions (Dus-
tin and Springer, 1989 ; van Kooyk et al ., 1989) . Activation
with phorbol ester or through otherT cell surface molecules
and their ligands (e.g., CD2/LFA-3) results in a more
prolonged LFA-1/ICAM-1 interaction (van Kooyk et al .,
1989) . As similar results using T cells have been obtained
for VLA-4, VLA-5, and VLA-6 (Shimizu et al ., 1990),
different integrins may employ common activation pathways .
We have recently described a unique mAb (24) that binds
to an epitope present on the a subunits of all three leukocyte
integrins (Dransfield and Hogg, 1989 ; Dransfield et al.,
1990, 1991) . Recognition of this epitope in the intact hetero-
dimer is Mgt+-dependent and for intact cells, expression
parallels receptor activity. We have therefore suggested that
1527control ofthe affinity of Mgt+ binding represents a potential
mechanism for regulation of receptor function (Dransfield
and Hogg, 1989) . The effect ofmAb 24 on leukocyte integrin
function has been analyzed using three systems which are
leukocyte integrin-dependent, namely, antigen presentation
by monocytes to T cells (Dougherty and Hogg, 1987) and
lymphokine-activated killer (LAK) cell cytotoxicity assays
(Robertson et al., 1990) which are both LFA-1 dependent
plus f-Met-Leu-Phe-stimulated chemotaxis ofneutrophils, a
response that has been found to be CR3-dependent (Ander-
son et al., 1986) . These functions were inhibited by mAb 24,
implicating the recognized epitope as a functionally impor-
tant region ofthe leukocyte integrins. Surprisingly, when ac-
tivated leukocyte integrins are binding to ligand, mAb 24
promoted rather than inhibited, indicating that functional
effects of antibody occur after receptor occupancy. Studies
using a model system for analysis of sequential activation and
deactivation of LFA-1 function suggest that mAb 24 acts to
prevent deactivation events, possibly by locking LFA-1 in the
ligand-bound "active" form.
Materials andMethods
Monoclonal Antibodies
Antibodies used in this study were mAb 24 (Hogg and Selvendran, 1985 ;
Dransfield and Hogg, 1989), 38 (CDlla) (Dransfield and Hogg, 1989), 44
(CDllb) (Malhotra et al., 1986), 14 (CD8) and MOPC21, a gift from Dr.
Gordon Ross (University of Louisville, Louisville, KY). MAb 15.2 was
characterized as an ICAM-1 mAb (CD54) by positive staining of ICAM-
1-transfectedL cells, irnmunoprecipitation, cell binding studies, andblock-
ing of LFA1/ICAM-1-dependent adhesion assays as reported herein. All
mAbs were purified by protein A chromatography (Ey et al., 1978). Fab'
fragments ofmAb24 were preparedby pepsindigestion (1% wt/wt) ofintact
IgGI mAb 24 in order to generate (Fabh fragments which were subse-
quently reduced with 0.01 M cysteine for 1 h at room temperature and
blocked for a further hour with 0.03 M iodoacetamide. Any intact IgG and
(Fay)2 fragments were separated from Fab24 by extensive adsorption with
protein A-coupled Sepharose followed by fractionation using gel filtration
chromatography. Analysis of 10 !rg of Fab24 by SDS-PAGE showed it to
be free of any such contaminants (results not shown).
CellsandCellLines
The lymphoblastoid B cell line JY (Rothlein et al., 1986), Burkitt's lym-
phoma cell line Daudi (Robertson et al., 1990), T cell lymphoma cell lines
SKW3 and J6(Rothleinet al., 1986; Staunton etal., 1989) were maintained
in RPMI 1640 plus 10% FCS. Activated T cells were expanded from un-
stimulated peripheral blood mononuclear cells (PBMC) by treatment with
phytohaemagglutinin(PHA; 10kg/ml; Pharmacia Fine Chemicals, Piscata-
way, NJ) andphorbol-12,13-dibutyrate(PdBu; 50 nM; Calbiochem-Behring
Corp., La Jolla, CA) for 48 h. Cells were washed and cultured in RPMI
1640 containing 10% FCS and 10% supernatant from the IL-2 producing
cell line MLA. After 1-2 wk ofculture, quiescence was induced by removal
ofIL-2 from the culture medium for 2-3 d. The resulting quiescent T cells
serve as a model foranalysis of T cell activation (Cantrell and Smith, 1984;
Cantrell et al., 1985).
GenerationofAntigen- andMitogen-induced
ProliferativeResponses
PBMC (2 x 105 cells) were cultured in 200 Al of RPMI-1640 containing
5% heat-inactivated, single donor human AB serum in 96-well flat bot-
tomed tissue culture plates (Becton-Dickinson) in the presence of influenza
virus at 1 Pg/tnl (Dougherty and Hogg, 1987; Dougherty et al., 1988) or
mitogens PHA and pokeweed mitogen (Sigma Chemical Co.) at doses of
1 or 0.1 kg/ml. After titration to ensure use of saturating concentrations of
antibody, the mAbs 14 (CD8), 44(CD11b), 38 (CD11a), and mAb 24 were
used either as purified IgG at 50 pg/ntl or as Fab' fragments 20 pg/ml (mAb
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24 only). Cultures were pulsed with 1 ACi/well 3H-thymidine for 4 h on
day 6 for antigen responses and on day 3 for mitogen responses.
Lymphokine-activatedKiller CellAssay
The LAK cell assay was performed essentially as described by Groscurth
et al. (1990) and Robertson et al. (1990) with some modification. Daudi
cells were used as targets and were labeled with 0.1 mCi of 5'Cr for 90 min
in 500 P1 ofRPMI 2 % FCS at 37°C. After two washes in RPMI 1640, the
cells were incubated at 37°C for an additional period of 60 min, washed
again, and resuspended in RPMI 1640. T cells cultured for 13 or 14 d in
the presence of IL-2 (see Cells and Cell Lines) were used as effector cells.
Thecytotoxicity assay was performed in quadruplicate in96-well U-bottom
plates (Flow Laboratories Inc., McClean, VA), by adding 4 x l0° labeled
target cells/well plus various concentrations of effector cells resulting in
effector to target cell ratios ranging from 60:1 to 3.7:1 in a final volume of
150 pl. For antibody inhibition studies, purified anti-CD1la mAb 38, mAb
24 and control mAb MOPC 21 were used at 50 pg/ml . After centrifugation
at 50 g for 2 min, the plates were incubated at 37°C for 5 h. Finally, the
plates were centrifuged again for 2 min at 50 g and 37.5 Al of supernatant
from each well were removed and counted. The relative percentage oflysis
was calculated using the formula:
100 x
experimental 5'CR release - spontaneous 5 Cr release
total 5'Cr release - spontaneous release
Neutrophil Chemotaxis
Neutrophil chemotaxis was measured using the sub-agarose method (Nel-
son et al., 1975; Chenoweth et al., 1979) with some modifications. Neutro-
phils were pretreated for 10 min with mAbs 14, 44, 38, and 24 either as
ascitic fluid (1:50) or purified mAbs (IgG, 35 Wg/ml or Fab24, 201og/ml).
Clean glass microscope slides were dipped in 0.5 % gelatin (Sigma Chemi-
cal Co.), rinsed anddried, coveredwith 5 ml ofmolten 1 % agarose (Indubi-
ose)/0.25% gelatin in medium 199 (Flow Laboratories) supplemented with
1% BSA and finally cut with a pattern-former giving two sets of three
wells/slide. The neutrophils (8 Al at 5 x 107/ml in medium 199/1% BSA)
were added to the central wells and 8 Al aliquots ofmedium 199/1% BSA,
plus or minus f-Met-Leu-Phe (final concentration 10-7 M; Sigma Chemi-
cal Co.) were added to the two outer wells, respectively. The slides were
incubated for 2 h at37°C, fixed for 18 h in 2 .5% glutaraldehyde and stained
with Diff-Quik Staining Set (Merz & Dade, Switzerland) . Migration dis-
tances ofduplicate samples were measured by determining the leading edge
ofneutrophil mobility forbothdirected and random migration using a Zeiss
14 microscope with 160-fold magnification. Chemotactic response was de-
fined as the specific migration toward the chemoattractant f-Met-Leu-Phe.
CellularAggregationAssay
1.5 x 105 JY, SKW3, J6 cell lines or quiescent cultured peripheral blood
T cells (see later) inRPMI 1640 containing 10% FCS were addedto96-well
tissue culture plates and aggregation was observed after incubation at 37°C
for varying periods of time. In some samples, aggregation was induced by
addition of 20 nM PdBu. Percentage of aggregating cells was assessed by
enumeration ofaggregate formation as follows (total number ofcells added
- numberof free cells)/total number ofcells added x 100. Each assay was
performed in triplicate and a minimum of 400 cells were counted for each
sample. mAbs 38 (CDlla), 15.2 (CD54), MHM23 (CDl8), and mAb 24
were added before the induction of aggregation and used either as purified
IgG (20 gg/ml) or as ascitic fluid (1:100). These amounts were at saturating
concentrations as determined by flow cytometric analysis.
iC3b Rosette Formation
Monocyte-derived macrophages were prepared by seeding PBMC into 96-
well plates at 2 x 106/ml in RPMI/1% pooled human AB serum. After
1 h, nonadherent cells were removed and adherent monocytes cultured for
4 din RPMI/1 % pooledAB serum beforeusein binding assays. iC3b-coated
erythrocytes (iC3b-E) were prepared from C3b-E (a generous gift of Drs.
G. Ross and R. B. Sim) as previously described (Malhotra et al., 1986).
iC3b-E were washed twice in HGVB++ buffer (20 mM Hepes, pH 7.4, 0.14
M glucose, 71 mM NaCl, 1 g/1 gelatin, 0.15 mM CaC12 and 0.5 mM
MgC12) and resuspended at 3 x 109/ml in HGVB++ and 0.2 mCi of "Cr
(Amersham Inc., Amersham, UK) added. After labeling for 1 h, cells were
washed twice in HGVB' before use. 6 x 101 labeled iC3b-E were added
to each well containing monocyte-derived macrophages and plates were
1528spun at 200 g for 30 s to bring cells into contact. After incubation at 37°C
for 45 min, unbound iC3b-E were removed by washing and surface-bound
iC3b-E lysed using 0.84% NH4C1 and counted for 51Cr using a Beta-plate
counter (LKB Instruments, Inc., Uppsala, Sweden). Forantibody inhibition
studies macrophages were preincubated with saturating concentrations of
ascitic fluids (typically 1:100 dilution) of mAbs 44 (CD11b), MHM23
(CDl8), or 24. Fab' fragments ofmAb 24 were used at a final concentration
of 20 jig/ml.
BindingofTCells to ICAM1
T cells (790% CD3 positive) were prepared from PBMC by passage over
a nylon wool column ofcells that were nonadherent to plastic (Julius et al.,
1973) or were expanded in culture with IL-2 (see Cells and Cell Lines).
These cells were labeled at 3 x 10' cells/ml in RPMI/10% FCS with 1
MCi of 51Cr (Amersham Corp.), incubated for 30 min on ice in 3 jug/ml
ofbiotinylated mAb UCHTI (Beverley and Callard, 1981) washed once in
ice-cold medium, and then incubated a further 30 min on ice in 10 pg/ml
ofgoat antibiotin antibodies (Sigma Chemical Co.). Alternatively, using a
second system of CD3 cross-linking, T cells were incubated with UCHTI
(IgG2a isotype; 1/5 tissue culture supernatant) on ice for 20-30 min before
washing and further incubation with goat anti-mouse IgG2a antibodies
(1/100; Nordic Immunology, Maidenhead, UK) using similar conditions.
These labeled cells (5 x 105 cells/well) were added to 96-well tissue cul-
ture plates containing either confluent monolayers of ICAM-1-transfected
CHO cells (a gift from D. Sansom and J. Trowsdale, Imperial Cancer Re-
search Fund) or recombinantICAM-113c proteinat 160 ng/well as previously
described (Dransfield et al., 1992) with the addition of mAb 24 IgG (20
ug/ml) or 24 Fab' fragments (10 pg/ml) in the presence or absence of anti-
LFA-1 a subunit mAb 38 (15jug/ml) or anti-ICAM-1 mAb 15.2 (15 ug/ml).
Plates were then centrifuged at 100 g for 1 min and incubated for 10, 20,
40, or 110 min at 37°C. Wells were washed five times in warm RPMI-1640
beforecell lysiswith PBS containing 1% NP-40. Lysates were counted using
a Betaplate counter (LKB Instruments, Inc.).
Results
LFA1-dependent TCellProliferative ResponsesAre
Inhibitedby mAb24
The proliferative response ofPBMC to the antigen influenza
virus is inhibited by mAb 24 and anti-CDI la mAb 38 but not
by other control ntAbs such as anti-CD1lb mAb 44 or CD8
mAb 14 (Fig. 1 a). Inhibition of these responses by mAb 24
may occur as a result of cross-linking of surface integrin
receptors through the use of whole IgG. However, we show
a
no mAb
￿
CD8
￿
CD11b
￿
CD11a
￿
mAb24
￿
Fab'24
￿
MMAbMAb2l CD112MOPC21
Dransfield et al. Mgz* Epitope and Leukocyte Integrin Function
Monoclonal antibody
in this study that Fab' fragments as well as intact mAb 24 are
inhibitors of leukocyte integrin function, indicating that the
observed inhibition is not a result of mAb-induced receptor
clustering. In contrast to the effects ofmAb 24 upon antigen-
specific T cell proliferation, when PBMCs were treated with
PHA (Fig. 1 b) or pokeweed mitogen (Fig. 1 c), at 1 gg/ml,
there was no inhibition of T cell responses by mAb 24 (or
by CDlla mAb 38). Therefore, mAb 24 was neither cyto-
toxic for these cells nor responsible for transducing regula-
tory signals preventing proliferation .
mAb24Affects theSizeofCellular Aggregates during
Antigen Stimulation
When PBMCs are stimulated over a 6-d time course, with
antigens such as influenza virus and purified protein deriva-
tive oftuberculin, large aggregates ofproliferating cells form
(Fig. 2 a) . Such aggregation can be prevented by CDl la mAb
(Fig. 2 b) and is not seen in control cultures without added
antigen. In the antigen-stimulated samples cultured in the
presence of mAb 24, there is formation of small aggregates
over the initial time period of 8-10 h not seen in the absence
of 24 (Fig. 2 c) . These small aggregates remain constant in
appearance over the assay time period. Furthermore, they do
not form in the presence of mAb 24 when CDl la mAb is also
present, indicating that LEA-1-dependent adhesions are re-
quired (data not shown). These observations suggest that
mAb 24 affects normal cellular motility and/or cell-cell con-
tact resulting in an increase in size ofcellular aggregates dur-
ing stimulation by antigen. As a consequence, further
progression of the proliferative response may be inhibited .
LAK Cell Cytotoxicity Is Inhibitedby mAb 24 atLow
EITRatios
T lymphoblasts cultured for 12-14 d in the presence of IL-2
were incubated for 5 h with Daudi cells at effector/target
(E/T) cell ratios ranging from 60:1 to 3.7:1. At the highest
E/T ratios the cytotoxic interaction was only partly inhibited
by a CDlla mAb and not by mAb 24 (data not shown) . At
1529
m MAb
￿
mAb24
￿
CD11a MOPC21
Figure 1. Effect of mAb 24 on
antigen-specific T cell prolif-
eration. (a) The proliferative
response ofPBMC to the anti-
gen influenza virus, was inhib-
ited by tnAb 24, Fab'24, and
by CDlla mAb 38, but not by
CDl lb nAb 44 or CD8 niAb
14. The mitogenic response of
PBMC to (b) PHA and (c) to
pokeweed mitogen was not in-
hibited by mAb 24, CDlla
mAb 38, or control mAb
MOPC 21. In the represen-
tative experiment shown, the
donor response to influenza
virus yielded 65,168 t 6,071
cpm, to PHA yielded 66,040
t 4,452 and to pokeweed mi-
togen, 36,303 t 2,493. The
results of quadruplicate sam-
ples are expressed as a percent-
age of the total counts f SE.Figure 2. Aggregate formation during response of PBMC to anti-
gen . (a) Aggregates formed by PBMC after 6 d ofexposure to anti-
gen, purified protein derivative oftuberculin . (b) Aggregate forma-
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Figure 3. Effect ofmAb 24 on
LAK activity. TheLAK activ-
ity of T cells cultured in IL-2
for 14 d against Daudi cells
was inhibited by mAb 24 . The
LFA-1 dependence ofthisLAK
activity is demonstrated with
anti-CD1 lamAb 38. ThemAb
MOPC 21 was used as a
control .
lower E/T ratios (15 :1 and particularly at 3 .7:1) the assay
became CDlla-dependent and could be correspondingly
blocked by mAb 24 (n = 5) . A typical experiment is shown
in Fig . 3. This result also suggests that mAb 24 might affect
cell motility or reduce opportunities for cell-cell contact un-
der circumstances where effector cells were limiting .
Neutrophil Chemotaxis Is Inhibited by mAb 24
The directed movement of neutrophils toward the chemoat-
tractant f-Met-Leu-Phe is inhibited by mAbs specific for the
leukocyte integrin CR3 (Anderson et al ., 1986) . A sub-
agarose assay (Nelson et al., 1975 ; Chenoweth et al ., 1979)
has been used to assess the effects of mAb 24 upon CR3-
dependent neutrophil chemotaxis . Inhibition of neutrophil
f-Met-Leu-Phe-directed migration was observed with use of
CDllb mAb 44, mAb 24 and Fab'24 but not with CDlla
mAb38 nor CD8 mAbl4 (Fig . 4, a and b) . Therefore, mAb
24 is able to inhibit both LFA-1-dependent functions and also
the activity of CR3, consistent with the observation that all
three CDll a subunits express the 24 epitope .
mAb 24DoesNotBlock Leukocyte Integrin
Binding to Ligand
To analyze more directly the possibility that mAb 24 might
affect the ability of leukocyte integrins to interact with
ligand, we analyzed the effects of mAb 24 upon inte-
grin/ligand binding using phorbol ester-induced aggregation
of the JY and SKW3 cell lines which were LFA-1/ICAM-1
and LFA-1/ICAM-2,3-dependent, respectively, (Rothlein et
al ., 1986 ; Staunton et al ., 1989 ; de Fougerolles et al., 1991)
and binding of iC3b-E to tissue culture-matured monocytes
which is CR3/iC3b dependent . Although anti-LFA-1 mAb
blocked the LFA-1-mediated aggregation assays (Fig . 5, a
and b) and anti-CR3 mAb inhibited the CR3-mediated roset-
ting assay (Fig . 5 c), no inhibition was observed with mAb
24 indicating that this mAb does not prevent receptor/ligand
binding.
tion is inhibited by CDl la mAb 38 indicative of LFA-1 dependence.
(c) Small clusters formed in the presence ofmAb 24 maintain con-
stant appearance throughout the 6-d period . Bar, 100 jAm .
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Figure 4. Effect ofmAb 24 on neutrophil chemotaxis stimulated by
f-Met-Leu-Phe. The chemotactic responseof neutrophils, using the
sub-agarose assay, was inhibited by mAb 24, Fab' 24, and CDlla
mAb 44, but not by CDlla mAb 38 or CD8 mAb14. In a, mAbs
were used as ascitic fluid (1:50) ; in b CD8 mAb 14 and CD1lb mAb
44 were used as purified IgG at 35 j,g/nil and Fab'24 at 20 pg/ml.
Results in a are the mean f SE of four separate experiments and
in b the mean of two experiments.
mAb24Enhances AggregateFormationin
PdBu-treated Cells
CDa CDttb Fab'24
Although mAb 24 did not inhibit leukocyte integrin/ligand
interaction, it remained to be tested whether the negative
effects of mAb 24 on leukocyte function were caused by an
enhancement of leukocyte integrin/ligand binding. There-
fore, mAb 24 was first tested for ability to directly cause the
aggregation of a T cell line J6, which expresses both LFA-1
and ICAM-1 (Hogg and Horton, 1987) but grows in single
cell suspension. mAb 24 (5014g/ml) did not cause aggregate
formation in these cells over a time period of 22 h (data not
shown). Secondly, we wished to test the effect of mAb 24 on
a cell line that undergoes spontaneous LFA-1/ICAM-1-de-
pendent aggregation. Therefore, mAb 24 (50,ug/ml) or PdBu
was added to dispersed cultures of the B cell line JY and the
cells observed for any alteration in the rate of cellular aggre-
gation. Fig. 6 shows that the rate of spontaneous aggregation
is enhanced by PdBu over a 2-h period. Similarly an en-
hanced rate of aggregate formation is observed in the pres-
ence of mAb 24, comparable to that induced by PdBu . It was
therefore concluded that mAb 24 was not able to induce
LFA-1 activation de novo but was able to promote that which
was already underway.
In a similar type of experiment, quiescent T cells at 1.5
x 101 cells/ml were incubated without (Fig. 7, a and b) or
with 20 nM PdBu (Fig. 7, c-f) and the effect of mAb 24 (50
t.g/ml) on aggregate formation was observed. There were no
aggregates visible in control cultures without or with mAb
24 (Fig. 7, a and b) or in cultures with 20 nM PdBu at 30
min (Fig. 7 c) . In this system, pronounced aggregation was
observed only after 90 min in the presence of PdBu (Fig. 7
e). However, when quiescent T cells were cultured in the
presence ofmAb 24 and PdBu, cellular aggregates were ob-
served at the earlier time point of 30 min (Fig. 7 d). After
Dransfield et al . Mg" Epitope and Leukocyte Integrin Function
t
90 min, aggregates formed in the presence of both PdBu and
niAb 24 were similar in appearance to those in the presence
of PdBu alone (compare Fig. 7, e andf) . Thus, in a second
system, mAb 24 hastened the formation of cellular aggre-
gates only under circumstances where LFA-1 was in an acti-
vated form.
1531
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￿
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Monoclonal antibody
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Figure 5. Effect of mAb 24
on LFA-1/ICAM-1,2,3-depen-
dent aggregationand on macro-
phage/iC3b-coated erythrocyte
CR3-dependent rosetting. (a)
Phorbol ester-induced LFA-I/
ICAM-1-dependent aggrega-
tion ofJY lymphoblastoid cell
line is inhibited by CDlla,
CD18, and CD54 (ICAM-1)
mAbs, but not inhibited by
mAb 24. (b) Phorbol ester-
induced LFAVICAM-2,3-de-
pendent aggregation of SKW3
T cell lymphoma cell line is in-
hibited by CDlla, CD18 mAbs
but not by mAb 24 or CD54
mAbs. (c) Binding of iC3b-E
by monocyte-derived macro-
phages (CR3-dependent) is
inhibited by CDllb, CD18
mAbs but not by mAb 24.
Results, representative of at
least three experiments, are
expressed as mean f SD of
triplicates.
Figure 6. Influence of mAb 24
on spontaneous aggregationof
JY cell line. After disruption
to single cell suspension, JY
cells spontaneously aggregate
(-o-) . The rate of aggregation
is enhanced by mAb 24 (+)
and PdBu (20nM) (-o-) and
is inhibited by CD18 mAb
MHM 23 (-n-) . Results, rep-
resentative of at least three ex-
periments, are expressed as
the mean f SD of triplicates.Figure 7 . Influence of mAb 24 on PdBu-induced aggregation of quiescent T cells . (a) Control culture of quiescent T cells (b) with mAb
24 (50 jig/ml), 30 min (c) PdBu (20 nM) alone, 30 min (d) PdBu and mAb 24, 30 min (e) PdBu alone, 90 min. (f) PdBu andmAb 24,
90 min. The percentage of cells participating in aggregates has been indicated for each experimental condition . Bar, 150 1m .
Tlransient Increase in LFA1 Avidity Is Prolonged
￿
have utilized a system for analyzing LFA-1-dependent adhe
by mAb 24
￿
sion ofTcells toICAM-1 which serves as amodelofactiva-
tion andsubsequent deactivation ofLFA-1 ligand binding ac-
To further explore the effect ofmAb 24 on leukocyteintegrin
￿
tivity (Dustin andSpringer, 1989). Twotypes of experiments
function in the absence of blockade of ligand binding, we
￿
were performed . Either freshly isolated T cells or IL-2 cul-
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￿
1532Figure 8. Reversible LFA-
1-dependent T cell binding to
ICAM-1 induced by CD3 cross-
linking is prevented by mAb
24. Cross-linking of CD3
caused rapid, transient adhe-
sion of (a) cultured T cells ad-
hering to ICAM-1Fc or (b)
freshly derived T cells adher-
ingto ICAM-1 expressing CHO
cells (XL-CD3) in contrast to
prolonged adhesion observed
in response to treatment with
PdBu (PdBu). Cross-linking
ofCD3 in thepresence ofmAb
24 IgG (XL-CD3 + 24(IgG])
or Fab' fragments (XL-CD3 +
24(FaY]) prolonged activated
Tcellbinding. Addition ofFab'
fragmentsofmAb 24 alonedid
not induce T cell adhesion
(mAb24 alone) . Specific adherence was blocked by CDlla mAb38 (+CD11a) and CD54 mAb15.2 (data not shown) which reduced adher-
ence to the level of untreated samples (no treatment). Binding of T cells to untransfected CHO cells was not detectable. Results (mean
of triplicates f SD) are representative of a minimum of four separate experiments.
Discussion
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tured T cell blasts were tested for binding to either ICAM-1
transfected CHO cells or to recombinant ICAM-1Fc. Rapid,
transient adhesion of T cells to ICAM-1 was observed upon
crosslinking of the TcR using CD3 mAbs, in contrast to the
prolonged adhesion induced by the phorbol ester PdBu (Fig.
8, a and b). We consistently found that cultured T cells
bound with greater efficiency than freshly isolated T cells.
Specific T cell binding was blocked by CDlla mAb 38 or
ICAM-1 mAb 15.2 (see Fig. 8 legend). Addition of whole
IgG as well as Fab' fragments of mAb 24 had a profound
effect upon the duration of adhesion induced by TcR cross-
linking. Thus in the presence of mAb 24, similar or fre-
quently enhanced levels of binding were reached within
20'-25; but reduction in the numbers of T cells bound to
ICAM-1 after prolonged incubation was not observed . Fab'
fragments ofmAb 24 in the absence ofcross-linked CD3 had
no effect on T cell adhesiveness. These results demonstrate
that the presence of mAb 24 prevents the de-adhesion of
LFA-1 and ICAM-1 . Our speculation is that mAb 24 main-
tains LFA-1 in the activated state and therefore inhibits post-
receptor occupancy changes required for release of ligand.
Leukocyte integrins are transiently activated through intra-
cellular signalling pathways enabling increased avidity of
binding to occur to counter receptors or ligands. To gain un-
derstanding of this activation process, we have further ana-
lyzed the effects on function ofa novel mAb 24, which recog-
nizes a Mgz+-dependent epitope present on all three
leukocyte integrin a subunits (Dransfield and Hogg, 1989).
mAb 24, as intact IgG or Fab' fragments is able to inhibit
antigen-specific T cell proliferation and LAK cell cytotoxic-
ity, which are LEA-1-dependent, and f-Met-Leu-Phe-stimu-
lated chemotaxis, which is a CR3-dependent process. There
are several possible explanations for the inhibitory effects of
this mAb. In some studies, mAbs to the 02 subunit of leuko-
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cyte integrins have been shown to transduce negative regula-
tory signals to T cells (van Noesel et al ., 1988) and a similar
mechanism might be operative for mAb 24. Alternatively,
mAb 24 might be cytotoxic for functioning cells. However,
analysis of T cell responsiveness induced by mitogen showed
that proliferation was unaffected by the presence of mAb 24
indicating that binding to its « subunit epitope was not
delivering an antiproliferative signal.
Another possibility is that the inhibitory effects ofmAb 24
on function might occur as a result of blockade of recep-
tor/ligand binding. Peptide ligands, RGD and fibrinogen y
chain sequences, can be cross-linked to the putative cation
binding domains of the 03 integrins, VNR and IIb/IIIa
(D'Souza et al ., 1990; Smith and Cheresh, 1990; Smith and
Cheresh, 1991). These observations have suggested that for
integrins, divalent cation binding and interaction with ligand
are intimately associated. However, the lack of an effect of
mAb 24 on LFA-1- or CR3-dependent binding assays, sug-
gests that the leukocyte integrins may interact with ligand in
a different manner to RGD-specific integrins. Another possi-
bility is that the 24 epitope, which behaves as an indicator
of Mgz+ binding, is not physically located within the puta-
tive cation binding domains. The localization of this epitope
is under investigation.
Although the inhibitory effect upon function of mAb 24
does not occur as a result of blocking receptor/ligand bind-
ing, it was of interest to know whether the mAb promoted
this type of interaction . There was no induction of aggrega-
tion when mAb 24 was added to J6 T cell line growing in
single cell suspension, indicating that it does not directly in-
duce LFA-1/ligand binding on these cells. However, when
mAb 24 was added to JY cells undergoing spontaneous
aggregation or PdBu-stimulated T cell aggregation, it was
able to enhance LFA-1-dependent interactions which were
already underway. These observations, coupled with previ-
ous work showing that the 24 epitope is expressed only when
LFA-1 is functionally active (Dransfield and Hogg, 1989;Dransfield et al., 1990), suggest that mAb 24 is able to pro-
mote an increase in LFA-1-dependent binding to ligand only
following prior activation of LFA-1. One explanation might
be that mAb 24 induces intracellular signals, enabling LFA-1
to combine with ligand with increased avidity. Such activity
has been suggested for other LFA-1 a subunit mAbs that en-
hance proliferation, rather than inhibit function (van Noesel,
1988; Carrera et al ., 1988; Wacholtz et al. 1989; Pardi et
al ., 1989). However, inhibitory effects on function might oc-
cur if mAb 24 acts extracellularly by blocking conforma-
tional alterations resulting from activation.
To test these possibilities, we analyzed the effect of mAb
24 in an assay that allows analysis of activation and subse-
quent deactivation of LFA-1 binding activity to ICAM-1
(Dustin and Springer, 1989). mAb 24 had no effect on the
rate of initial adhesion of T cells. However, the resulting
prolongation of the initial adhesion phase by mAb 24 sug-
gests that, by interacting with its epitope, mAb 24 prevents
de-adhesion of LFA-1 and ICAM-1. It can be speculated that
LFA-1 is unable to dissociate from ICAM-1 because an es-
sential conformational alteration of the a and ß subunits is
prevented. Further evidence for this suggestion comes from
the formation of small aggregates in antigen-stimulated cul-
tures of peripheral blood cells in the presence of mAb 24.
These aggregates form after a few hours exposure to antigen
and subsequently appear to remain stable in size. One possi-
bility is that access of other T cells to adherent antigen-pre-
senting cells is prevented, thus precluding further stimula-
tory events. Similarly the ability ofmAb 24 to prevent LAK
cytotoxicity increased as the effector/target cell ratio de-
creased which could be explained by an increased depen-
dence on effector cell recycling. Finally it can be speculated
that neutrophils moving on a substrate in a chemotactic gra-
dient might accomplish this end at least partly via an
attachment-release mechanism involving CR3 as has been
demonstrated for neutrophil binding to endothelium (Wright
and Meyer, 1986; Lo et al ., 1989) .
Recognition of leukocyte integrin a/ß heterodimers by
mAb 24 is unique. As mAb 24 does not induce adhesion, it
differs from mAbs recognizing LFA1 directly (Keizer et al.,
1988; van Kooyk et al., 1991) or indirectly (Hong et al.,
1989; Mourad et al., 1990; Lauener et al ., 1990; Koopman
et al., 1990), which increase avidity of LFA-1 binding to
ligand. The inhibitory effects of mAb 24 on leukocyte inte-
grin function contrast with anti-LFA-1 mAb NKI-L16 that
acts extracellularly to promote ligand binding activity (Keizer
et al., 1988; van Kooyk et al., 1991) . This might be ex-
plained if mAb 24 prevents release of ligand from activated
LFA-1 rather than, as observed for NKI-L16, promotes initial
stages of LFA-1/ligand interaction. The formation of large
aggregates in the presence of NKI-L16 would not preclude
dynamic interaction of leukocytes necessary for functions
such as antigen presentation. In contrast, the functional
effects ofmAb 24 may be a direct result ofprevention of such
dynamic interaction. In this respect, mAb 24 is more similar
to mAbs recognizing ligand-occupied 03 integrins described
by Ginsberg and colleagues (Frelinger et al., 1988, 1990).
They observed that these mAbs, which by definition do not
prevent ligand binding, inhibit IIIb/IIIa-dependent functions
such as clot retraction, possibly by preventing release of
ligand.
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As mAb 24 does not interfere with binding of LFA-1 or
CR3 to ligand, the inhibition of chemotaxis and antigen-
specific T cell proliferation by this mAb occurs in spite of
engagement of leukocyte integrin with ligand. This may be
because receptors are unable to dissociate from ligand in the
presence ofmAb 24 as is observed in the transient LFA-1 ac-
tivation system triggered by CD3 cross-linking. Thus it may
be that mAb 24 causes leukocyte integrins to retain an "acti-
vated" conformation, preventing a return to the "nonacti-
vated" state. As a consequence, leukocyte integrin-depen-
dent functions are inhibited, implying a requirement for
dynamic receptor/ligand binding in these processes. In sum-
mary, we present evidence that conformational alterations as
detected by mAb 24 are a requirement for function in leuko-
cyte integrin-mediated processes.
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